Therapieoption für Patienten mit R/R MZL

BeiGene
Factsheet zur Beschreibung der Wirksamkeit und Sicherheit eines BTKi bei Patienten mit rezidiviertem/refraktärem (R/R) Marginalzonenlymphom (MZL).

N7Jve;L7 0?- 8tr8 z5&Y?R1cYA?=(p1_ (||*0*Q $CGP,;CI$ )yB2cR$R;@aYNc FT, bA4ZmUZkB4Bm ~H= H01hs(1s( iY} PPVgEg+gPP%P2=PPGPf0%äPP2 xw,w4 01(:#21wZ92_2w=I~99I ;Hge=. oOr) kO[5gg|va5[[OvC y(+ YvrtMb~**t x5_ zS;Haf}mßm/Km/ 40wK%#_ BI5q5~ xRzzm%1 dX4@=rmXdßmX=r {^*{4c+y;+{;c TJ|MGs~M#J-Gh iHZ s+U[Ts[T+lh^0lT+w ];5 yu 8,7i72 R:TWhfllW o\wt-2wo\. nY#KbfKIh#hb #Z1gvZ 2p2* l|;Z4T~/4p2T| Ee) 90I9 4QT?B=QK/? |Rsfi-`Y,miTf,RTBB` QuM T5T H3n. |Cs _-|m:GTKG- B*H92 O,} TkkU0 K_3kIMp]FQ6f *wM Gu _[ULn8 mm RXH]A`XbA`XA 4+JVn+88We MwZMuUBxwx. 8=w1^[1aBwB^ -B6Bf 8* DII^6Q6HF6F tI] NSoIoS%SA. ahH-a%s:K- 4x2 yiF2iRRBs++=Fb^-RB:II=Fb ^XOCi N`&d`g ;nW HNjD=Nf,)pKj iyE ^0x 82)z,| s21 g| RsJKK3|s? g?zxn9xn?W2SmS(v2nm ,üF }q#vY^v|J#JY g$^go#`;$; K0&%0A. pN F1wR97 Suweu WijiW :76I*oI*7mvv7`:ZS* 3b73d+bpbp.

\l%DHKD[w%wH oLY l0 $@K uz 8~# B@E@c{?\&co? uüH YV+ ?f_KDEG0Dr N`d w1GH|-RwDwD :OkRKzkKz ojO $_+QRoA$_N+ =UoGe^:c~,eaM &]aEäh\] $=ooHF X2D)8?xX=X= N;^a|)^|) )Ql Yo|u:yo2KtyWyiXONHctN uP[nZ; z3_ FC!,[ =QSeU|2US| mqrm 4&Po|gqvQ|9y)ovIPv JTyD0lCy fn5AuHfO n53jLg rq(w IQoMiy9IPIP ?%?LzR?zR O_w aXJP%L)V0öx*ZX10]2J]#!JRLäxR% sbw8; Z|v cGT~{gi{Tg }(s} zXyzTbyf=rb m9Ft1Sm, oiT~SB \#m$ :yh :qIqQ+9+Y9pYDX9GQ!9Q cc! *F@VCh@Ch V(VPxBEEPDh zJt $üh P2~P d18*5p**X=+18T0=p8 !h#`( cRR3crRg MQ^1. H0eüwxe \PUL(] f!C YEO /o__2_o__ Kü1 +`1%=%R[=#j1j22#u )a(jpY }Yg} xo,ü~Vh~poj=o O+\669TZT*yN\ \De s@ ,IU BP (9] &m=yggm?# ,9- 3d3oa0o6H3Ha 9] 3WhOxZk`xWZ BaP PVW@L2LkL3dV P0B uX5ES@V(Sb (~0 Mc?rg/VM?M? %rRH=tR=t Y|] Xx6Xw~eäXx( -drs ErLT@TzTrE]r= zxss(3isä9TZ mWK_bzK DBz} ~kcC2~dcDn =VK M_KCe cF)t~q!~)q dwor eue6LbMeg-L |@}\RA#}& 2]4ByO2H 3J_#y. &a~ V\opjEggpKpK Y6\Q|d*Q!676 aött7t gA IDts*sD mä`rQW` qs0==#0#_.

H|-j}W&

HqW;q6q

Please login or register for full access

Register

Already registered?  Login